Trastuzumab Deruxtecan in the Neoadjuvant Setting
Closing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.
The Emerging State of HER2-low Breast Cancer
Dr Geyer and Dr Krop discuss key data and the evolving standard of care for patients with HER2-low breast cancer.
Unmet Needs for Patients with HER2+ Breast Cancer with Brain Metastases
Breast cancer experts exchange thoughts on the treatment of HER2+ breast cancer with CNS involvement, particularly the use of trastuzumab deruxtecan in this subset of patients.
Key Takeaways from Clinical Trials of Trastuzumab Deruxtecan in Different Populations
Dr Krop leads a discussion of results from the DESTINY-Breast02 and DESTINY-Breast03 studies concerning the use of trastuzumab deruxtecan in patients with metastatic breast cancer.
Recent Updates for the Advanced HR+ Breast Cancer Setting
Charles E. Geyer, MD and Ian E. Krop, MD, PhD touch on recent advances in the metastatic HR+ breast cancer setting and evaluate PROTAC estrogen receptor (ER) degraders compared with other ER modulators.
Clinical Implications of SERENA-2 Trial Data
Conversation centered around the clinical implications of recently presented data from the randomized, multi-dose phase II SERENA-2 trial.
Novel Agents in the Adjuvant Setting: PARP Inhibitors
Dr Geyer and Dr Krop explore data from the OlympiA phase III trial of adjuvant olaparib in patients with variants in BRCA1/2.
Updates in the Treatment of Early-stage HR+ Breast Cancer
Two breast cancer experts review updates from the SOFT and TAILORx trials and discuss racial disparities in breast cancer treatment and clinical trials.
The Evolution of the Breast Cancer Treatment Landscape
Charles E. Geyer, MD and Ian E. Krop, MD, PhD provide an overview of the current breast cancer treatment landscape, with a focus on the management of patients with ER+/HER2- metastatic breast cancer.
Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer
Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.
Treatment Options for HER2+, ER+ Metastatic Breast Cancer
A panel of experts briefly reviews the treatment options available for patients with ER+, HER2+ metastatic breast cancer.
Special HER2+ mBC Populations: HR+ or HER2-Low Patients
Expert panelists discuss the optimal management patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.
Potential Role of Surgery in HER2+ Metastatic Breast Cancer
Shared insight on the potential role for surgery in the setting of HER2+ metastatic breast cancer in the context of pharmacologic therapy.
SABCS 2021: Small Molecule Clinical Trials in R/R HER2+ mBC
Rounding out their conversation on SABCS 2021, experts discuss small molecule–based treatment strategies for relapsed/refractory HER2+ metastatic breast cancer.
SABCS 2021: Combination Strategies Under Investigation for R/R HER2+ mBC
Considering data from the SABCS 2021 annual meeting, experts discuss novel combination strategies for relapsed/refractory HER2+ metastatic breast cancer.
HER2+ Breast Cancer: Updates on HER2CLIMB and CNS Disease Management
A brief review of updated data from HER2CLIMB and discussion on which agents may be best for treating patients with CNS disease.
Novel Treatment Approaches to R/R HER2+ Metastatic Breast Cancer
Experts discuss the role of novel therapies in relapsed/refractory HER2+ metastatic breast cancer accounting for results from recent clinical trial.
HER2+ mBC: Impact of T-DM1 and T-DXd Beyond the Frontline Setting
Shared insight on the roles of trastuzumab emtansine and trastuzumab deruxtecan in relapsed/refractory HER2+ metastatic breast cancer.
Monitoring Patients With HER2+ Metastatic Breast Cancer
A brief review of patient monitoring and screening practices in the setting of HER2+ metastatic breast cancer.
Patient Case: Frontline Treatment Options for HER2+ mBC
Taking into account a patient case of HER2+ metastatic breast cancer, experts review current frontline treatment options.
Patient Case: Biomarker Testing in Breast Cancer
Centered on a patient presentation of breast cancer, panelists consider optimal biomarker testing strategies to inform their treatment approach.
An Overview on the Current State of Metastatic Breast Cancer
Expert perspectives on the current treatment landscape of metastatic breast cancer and the unmet needs prevalent across various subsets of disease.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512